You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD30, r/r NHL, DLBCL, ALCL, ENKTCL, PMBCL, PTCL, adult

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Mature B-Cell Non-Hodgkin Lymphoma Trial (Obinutuzumab, Glofitamab, Rituximab)

Not yet recruiting
  • Mature B-Cell Non-Hodgkin Lymphoma
  • (no location specified)
Sep 6, 2022

DLBCL, Follicular Lymphoma Trial in United States (Epcoritamab)

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • Follicular Lymphoma
  • Fountain Valley, California
  • +38 more
Jul 27, 2022

Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Isophosphamide)

Not yet recruiting
  • Diffuse Large B-cell Lymphoma
  • (no location specified)
Mar 23, 2023

NHL, NHL, Relapsed, Adult Trial in United States (CLN-978)

Recruiting
  • NHL
  • NHL, Relapsed, Adult
  • Birmingham, Alabama
  • +4 more
May 31, 2023

Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent Trial in Italy (R-DHAP, Pola-R-DHAP)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma Refractory
  • Diffuse Large B-cell Lymphoma Recurrent
  • Alessandria, Italy
  • +39 more
Jul 28, 2023

Large B-cell Lymphoma Trial in Houston (Prednisone, Rituximab, Cyclophosphamide)

Not yet recruiting
  • Large B-cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Sep 19, 2023

Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory DLBCL Trial in United States (EZM0414)

Recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Relapsed/Refractory Diffuse Large B-Cell Lymphoma
  • Chevy Chase, Maryland
  • +10 more
Jan 12, 2023

Diffuse Large B-cell Lymphoma Trial in Switzerland (Acalabrutinib)

Recruiting
  • Diffuse Large B-cell Lymphoma
  • Bergamo, Italy
  • +16 more
Jan 17, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Follicular Lymphoma Trial in Australia, China (BGB-10188,

Recruiting
  • Chronic Lymphocytic Leukemia
  • +9 more
  • Adelaide, Australia
  • +12 more
Jan 6, 2023

Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell

Not yet recruiting
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
  • +5 more
  • Boston, Massachusetts
  • +1 more
Jun 28, 2023

Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial in United States (JCAR017 (lisocabtagene

Active, not recruiting
  • Non-Hodgkin Lymphoma
  • +4 more
  • JCAR017 (lisocabtagene maraleucel) single-dose schedule
  • JCAR017 (lisocabtagene maraleucel) 2-dose schedule
  • Birmingham, Alabama
  • +24 more
Nov 21, 2022

B Cell Non-Hodgkin's Lymphoma Trial in Duarte (CD19/CD20-directed CAR-T cells)

Recruiting
  • B Cell Non-Hodgkin's Lymphoma
  • CD19/CD20-directed CAR-T cells
  • Duarte, California
    City of Hope Medical Center
Aug 10, 2022

CD20-positive B-cell Non-Hodgkin's Lymphoma Trial in Beijing (IMM0306)

Recruiting
  • CD20-positive B-cell Non-Hodgkin's Lymphoma
  • Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Apr 6, 2023

Peripheral T-Cell Lymphoma (PTCL) Trial in Japan, Korea, Republic of (HBI-8000)

Completed
  • Peripheral T-Cell Lymphoma (PTCL)
  • Akita, Japan
  • +22 more
Jun 8, 2022

Multiple Myeloma, Non-Hodgkin Lymphoma, B-Cell Lymphoma Trial in Korea, Republic of, United States (Tiragolumab,

Active, not recruiting
  • Multiple Myeloma
  • +2 more
  • Denver, Colorado
  • +12 more
Jan 19, 2023

Large B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Homburg (R-miniCHOP + Acalabrutinib, R-miniCHOP)

Not yet recruiting
  • Large B-cell Lymphoma
  • Diffuse Large B Cell Lymphoma
  • Homburg, Saarland, Germany
    Saarland University Medical Center
Apr 19, 2023

Peripheral T Cell Lymphoma, PTCL, Extranodal NK/T-cell Lymphoma Trial in Worldwide (Tislelizumab)

Completed
Has Results
  • Peripheral T Cell Lymphoma
  • +18 more
  • Vancouver, British Columbia, Canada
  • +29 more
Apr 29, 2022

Lymphoma, Non-Hodgkin Trial in Worldwide (CC-96673)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Minneapolis, Minnesota
  • +11 more
Nov 18, 2022

Diffuse Large B Cell Lymphoma Trial in Shanghai (BTK inhibitor, PD-1 inhibitor)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • BTK inhibitor
  • PD-1 inhibitor
  • Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
May 20, 2023

Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Trial in Worldwide

Active, not recruiting
  • Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
  • Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
  • Brexucabtagene Autoleucel (KTE-X19)
  • +2 more
  • Los Angeles, California
  • +30 more
Nov 2, 2022

Diffuse Large B Cell Lymphoma Trial in Wuhan (Zanubrutinib plus RCHOP)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Zanubrutinib plus RCHOP
  • Wuhan, Hubei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Aug 16, 2023

Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)

Active, not recruiting
  • Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)
  • Yamagata, Japan
    Yamagata University Hospital
Feb 21, 2022

T-Cell Lymphoma Trial (Brentuximab vedotin, Pembrolizumab)

Not yet recruiting
  • T-Cell Lymphoma
  • (no location specified)
Jul 22, 2022

Diffuse Large B Cell Lymphoma (DLBCL) Trial in Shanghai (Orelabrutinib + R-CHOP, Placebo + R-CHOP)

Recruiting
  • Diffuse Large B Cell Lymphoma (DLBCL)
  • Orelabrutinib + R-CHOP
  • Placebo + R-CHOP
  • Shanghai, Shanghai, China
    Shanghai Ruijing Hospital
Nov 28, 2022

DLBCL Trial in Worldwide (Polatuzumab Vedotin, Rituximab, Cyclophosphamide)

Active, not recruiting
  • Diffuse Large B-Cell Lymphoma
  • Polatuzumab Vedotin
  • +7 more
  • Birmingham, Alabama
  • +242 more
Nov 23, 2022